Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Comorbidities in MS and NMOSD

Helen Tremlett, PhD, The University of British Columbia, Vancouver, Canada, talks about the comorbidities in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Comorbidities are more common in the MS population compared to matched general population controls even before the classical onset of MS. The most prevalent comorbidities present in MS patients are anxiety, depression, hyperlipidemia, and chronic lung disease. In the NMOSD population, less is known about the prevalence of comorbidities. However, a recent study suggests that Parkinson’s disease and ischaemic heart disease are more common in the NMOSD population than in the matched general population controls. The study also compared the NMOSD and MS populations and found that the risk of comorbidities investigated was similar between the two populations. Additionally, ongoing studies are investigating the association of comorbidities with the risk of future relapse and risk of future disability progression in MS to understand the relevance of comorbidities in those patients. Future research should focus on understanding if managing comorbidities could benefit MS patients by reducing relapse or disability risks. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Helen Tremlett has received research support in the last 3 years from the: Canada Research Chair Program, National MS Society, Canadian Institutes of Health Research, Canada Foundation for Innovation, MS Society of Canada, MS Scientific Research Foundation and the EDMUS Foundation (‘Fondation EDMUS contre la sclérose en plaques’).